Exogenous and Endogenous Adenosine Inhibits Fetal Calf Serum–Induced Growth of Rat Cardiac Fibroblasts
- 21 October 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 96 (8), 2656-2666
- https://doi.org/10.1161/01.cir.96.8.2656
Abstract
Background Because proliferation of cardiac fibroblasts participates in cardiac hypertrophy/remodeling associated with hypertension and myocardial infarction, it is important to elucidate factors regulating cardiac fibroblast proliferation. Adenosine, a nucleoside abundantly produced by cardiac cells, is antimitogenic vis-à-vis vascular smooth muscle cells; however, the effect of adenosine on cardiac fibroblast proliferation is unknown. The objective of this study was to characterize the effects of exogenous and endogenous (cardiac fibroblast–derived) adenosine on cardiac fibroblast proliferation. Methods and Results Growth-arrested cardiac fibroblasts were stimulated with 2.5% FCS in the presence and absence of adenosine, 2-chloroadenosine (stable adenosine analogue), or modulators of adenosine levels, including (1) erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA; adenosine deaminase inhibitor); (2) dipyridamole (adenosine transport blocker); and (3) iodotubericidin (adenosine kinase inhibitor). All of these agents inhibited, in a concentration-dependent manner, FCS-induced cardiac fibroblast proliferation as assessed by DNA synthesis ([ 3 H]thymidine incorporation) and cell counting. EHNA, dipyridamole, and iodotubericidin increased extracellular levels of adenosine by 2.3- to 5.6-fold when added separately to cardiac fibroblasts, and EHNA+iodotubericidin or EHNA+iodotubericidin+dipyridamole increased extracellular adenosine levels by >690-fold. Both KF17837 (selective A 2 antagonist) and DPSPX (nonselective A 2 antagonist) but not DPCPX (selective A 1 antagonist) blocked the antimitogenic effects of 2-chloroadenosine, EHNA, and dipyridamole on DNA synthesis, suggesting the involvement of A 2A and/or A 2B but excluding the participation of A 1 receptors. The lack of effect of CGS21680 (selective A 2A agonist) excluded involvement of A 2A receptors and suggested a major role for A 2B receptors. This conclusion was confirmed by the rank order potencies of four adenosine analogues. Conclusions Cardiac fibroblasts synthesize adenosine, and exogenous and cardiac fibroblast–derived adenosine inhibits cardiac fibroblast proliferation via activation of A 2B receptors. Cardiac fibroblast–derived adenosine may regulate cardiac hypertrophy and/or remodeling by modulating cardiac fibroblast proliferation.Keywords
This publication has 18 references indexed in Scilit:
- Adenosine Inhibits Growth of Rat Aortic Smooth Muscle CellsHypertension, 1996
- Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma.Journal of Clinical Investigation, 1995
- Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression.Journal of Clinical Investigation, 1995
- Harnessing an endogenous cardioprotective mechanism: Cellular sources and sites of action of adenosineJournal of Molecular and Cellular Cardiology, 1995
- Endothelial nucleotide catabolism and adenosine productionCardiovascular Research, 1994
- Increases in Interstitial Adenosine and Cerebral Blood Flow with Inhibition of Adenosine Kinase and Adenosine DeaminaseJournal of Cerebral Blood Flow & Metabolism, 1993
- (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonistsJournal of Medicinal Chemistry, 1992
- Adenosine: A Physiological Brake on Renin ReleaseAnnual Review of Pharmacology and Toxicology, 1991
- Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.Journal of Clinical Investigation, 1986
- Adenosine and the concept of ‘retaliatory metabolites’Trends in Biochemical Sciences, 1984